Amylyx Pharmaceuticals, Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $108.45 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 1.93%. This compares to year-ago revenues of $21.89 million. The company has topped consensus revenue estimates three times over the last four quarters.
The market isn't chucking them under the bus just yet judging by their SP movements in the past few weeks.
Strange times indeed. Revenue appears good which is the kicker.
PharmAust media thread, page-224
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 18.0¢ | $157.8K | 864.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 192000 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 73740 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.5¢ |
Change
0.005 ( 2.78 %) |
||||
| Open | High | Low | Volume | ||
| 18.0¢ | 19.0¢ | 18.0¢ | 248618 | ||
| Last updated 15.45pm 30/05/2024 ? | |||||
| PAA (ASX) Chart |